Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE.
EMTRICITABINE vs EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Emtricitabine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competing with natural substrates and causing chain termination after incorporation into viral DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to a hydrophobic pocket near the active site of HIV-1 reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (200 mg emtricitabine/25 mg rilpivirine/300 mg tenofovir disoproxil fumarate) orally once daily with a meal.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Emtricitabine: terminal half-life ~10 hours (clinical context: supports once-daily dosing; prolonged in renal impairment). Rilpivirine: terminal half-life ~50 hours (clinical context: supports once-daily dosing; long half-life allows missed dose forgiveness). Tenofovir: terminal half-life ~17 hours (clinical context: supports once-daily dosing; prolonged in renal impairment).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Emtricitabine: 86% excreted unchanged in urine via glomerular filtration and active tubular secretion; 14% as metabolites. Rilpivirine: ~85% fecal as unchanged drug (25%) and metabolites (60%); ~6% urinary. Tenofovir disoproxil fumarate: 70-80% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Category C
Category A/B
Antiretroviral, NRTI
NRTI